Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-05-07T05:35:30.240Z Has data issue: false hasContentIssue false
This chapter is part of a book that is no longer available to purchase from Cambridge Core

18 - Drug discovery and development

Keith Wilson
Affiliation:
University of Hertfordshire
John Walker
Affiliation:
University of Hertfordshire
Get access

Summary

HUMAN DISEASE AND DRUG THERAPY

Human disease

The wide range of diseases to which humans are exposed have in common the fact that each is the result of either some physiological dysfunction caused by a gene mutation or incorrect expression of the related protein, or of the exposure of the individual to an environmental factor, such as pesticides, diet, or bacterial, fungal or viral infection. The dysfunction gives rise to characteristic medical symptoms that enable the condition to be diagnosed, commonly by diagnostic tests of the type described in Chapter 16, and an evaluation made of the severity of the condition and the future prospects of the patient making a full recovery from it. Underlying many of the conditions at a molecular level is a change in the amount, function or activity of one or more proteins that in turn trigger changes in cellular, tissue or organ function. A large part of current worldwide medical research is aimed at the elucidation of the molecular mechanisms underlying diseases such as the various forms of cancer and neurological conditions such as Parkinson's disease, motor neurone disease and multiple sclerosis, in order to identify key proteins involved in the disease process with a view to selecting one of the proteins as a target for the development of a new drug and thereby to minimise or eliminate the symptoms.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

,Anonymous (2007). Guidelines on the Practice of Ethics Committees in Medical Research with Human Participants, 4th edn. London: Royal College of Physicians.
Crooke, S. T. (ed.) (2008). Antisense Drug Technology: Principles, Strategies and Applications, 2nd edn. New York: CRC Press. (Gives a review of the mechanisms of action, pharmacokinetics and therapeutic potential of antisense drugs in the context of a wide range of clinical conditions.)Google Scholar
Kshirsagar, T. (ed.) (2008). High-Throughput Lead Optimization in Drug Discovery. New York: CRC Press. (Uses real examples to illustrate the application of the technique in modern drug development.)CrossRefGoogle Scholar
Rang, H. P. (ed.) (2006). Drug Discovery and Development: Technology in Transition. London: Elsevier. (An in-depth coverage written in an authoritative style by experts from the pharmaceutical industry.)Google Scholar
Cross, D. M. and Bayliss, M. K. (2000). A commentary on the use of hepatocytes in drug metabolism studies during drug discovery. Drug Metabolism Reviews, 32, 219–240.CrossRefGoogle ScholarPubMed
Eichler, H.-G., Pinatti, F., Flamion, B., Leufkens, H. and Breckenridge, A. (2008). Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nature Reviews Drug Discovery, 7, 818–826.CrossRefGoogle ScholarPubMed
Ekins, S., Mestres, J. and Tasta, B. (2007). In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology, 152, 9–20.CrossRefGoogle ScholarPubMed
Gomez-Hens, A. and Aguillar-Caballos, M. P. (2007). Modern analytical approaches to high-throughput drug discovery. Trends in Analytical Chemistry, 26, 171–180.CrossRefGoogle Scholar
Imming, P., Sinning, C. and Meyer, A. (2006). Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery, 5, 821–832.CrossRefGoogle ScholarPubMed
Joy, T. and Hegele, R. A. (2008). Is raising HDL a futile strategy for atheroprotection?Nature Reviews Drug Discovery, 7, 143–154.CrossRefGoogle ScholarPubMed
Karlberg, J. P. E. (2008). Trends in disease focus of drug development. Nature Reviews Drug Discovery, 7, 639–640.CrossRefGoogle ScholarPubMed
Lagerstrom, M. C. and Schioth, H. B. (2008). Structural diversity of G-protein coupled receptors and significance for drug discovery. Nature Reviews Drug Discovery, 7, 339–357.CrossRefGoogle ScholarPubMed
Lindsay, A. C. and Choudhury, R. P. (2008). Form to function: current and future roles for atherosclerosis imaging in drug discovery. Nature Reviews Drug Discovery, 7, 517–530.CrossRefGoogle Scholar
Neil, S. J., Zang, T. and Bieniasz, P. D. (2008). Tetherin inhibits retrovirus release and is antagonised by HIV-1 Vpu. Nature, 451, 425–431.CrossRefGoogle Scholar
Rader, D. J. and Daugherty, A. (2008). Translating molecular discoveries into new therapies for atherosclerosis. Nature, 451, 904–912.CrossRefGoogle ScholarPubMed
Rognan, D. (2007). Chemogenomic approaches to rational drug design. British Journal of Pharmacology, 152, 38–52.CrossRefGoogle ScholarPubMed
Rose, A. D. (2008). Pharmacogenetics in drug discovery and development: a translational perspective. Nature Reviews Drug Discovery, 7, 807–817.CrossRefGoogle Scholar
Starkuviene, V. and Pepperkok, R. (2007). The potential of high-content high-throughput microscopy in drug discovery. British Journal of Pharmacology, 152, 62–71.CrossRefGoogle ScholarPubMed
Wang, C.-Y., Liu, P. Y. and Liao, J. K. (2008). Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine, 14, 32–44.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×